Key Performance
More- Earnings Score: 80
- Momentum Score: 26
- True Yield: N/A
- Financial Health Score: 59
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.
06/22/2026, 10:45 PM • GlobeNewswire
A securities fraud class action lawsuit has been filed against ADMA Biologics for allegedly making materially false statements about revenues and internal controls. The lawsuit covers investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. The stock dropped 29.1% after Culper Research published a report alleging channel stuffing and undisclosed related party transactions. The deadline to seek lead plaintiff status is August 10, 2026.
06/22/2026, 6:30 PM • GlobeNewswire
A class action lawsuit has been filed against ADMA Biologics for allegedly making false statements regarding revenue growth, engaging in channel stuffing, failing to disclose related party transactions, and lacking adequate internal controls. A short-seller report triggered a 16% stock decline, followed by a 13% drop after a downgrade from Cantor Fitzgerald.
06/19/2026, 2:15 PM • GlobeNewswire
The Schall Law Firm is seeking investors to join a class action lawsuit against ADMA Biologics, Inc. for securities fraud. The company allegedly made false and misleading statements, engaged in undisclosed related party transactions, used channel stuffing to inflate revenue, and failed to maintain proper internal controls during the period from August 9, 2024 to March 25, 2026.
06/19/2026, 9:56 AM • GlobeNewswire
A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud for the period between August 9, 2024 and March 25, 2026. The complaint claims the company engaged in undisclosed related party transactions, channel stuffing, and lacked adequate internal controls, resulting in materially false and misleading statements about its business operations and prospects.
06/18/2026, 12:00 PM • GlobeNewswire
ADMA Biologics faces a class action securities fraud lawsuit alleging the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenue growth. A March 2026 report by Culper Research claimed ADMA induced distributors to stock excess inventory through rebates and extended payment terms, reporting false growth figures. The allegations led to a 29.1% stock price decline. Investors have until August 10, 2026 to file a lead plaintiff motion.
06/18/2026, 12:00 PM • GlobeNewswire
A class action lawsuit has been filed against ADMA Biologics for allegedly making false statements about its business operations. The lawsuit claims ADMA engaged in undisclosed related party transactions, used channel stuffing to inflate revenues, and lacked adequate internal controls. Following a short report by Culper Research on March 24, 2026, ADMA's stock fell 16.63%. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 can join the lawsuit.
06/17/2026, 6:23 PM • GlobeNewswire
A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) for the period between August 9, 2024 and March 25, 2026. The complaint alleges material misstatements regarding revenues, undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. The stock dropped 29.1% following a Culper Research report exposing these practices on March 24, 2026.
06/17/2026, 11:00 AM • GlobeNewswire
A class action securities lawsuit has been filed against ADMA Biologics, Inc. for allegedly failing to disclose material information and making false statements. The complaint alleges undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. Investors who purchased securities between August 9, 2024 and March 25, 2026 may be eligible to participate, with an August 10, 2026 deadline to request lead plaintiff status.
06/16/2026, 11:28 PM • GlobeNewswire
Robbins LLP announced a class action lawsuit against ADMA Biologics for allegedly misleading investors regarding business operations. The complaint alleges undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. Following a March 24, 2026 Culper Research report exposing these issues, ADMA stock fell 16.6% on March 24 and an additional 15.0% on March 25, 2026.
06/15/2026, 6:21 PM • GlobeNewswire
A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. following allegations by Culper Research of channel stuffing, undisclosed related party transactions, and inflated revenue growth. The stock fell 29.1% on March 24-25, 2026, after the report alleged the company induced distributors to stock excess inventory using rebates and extended payment terms to artificially boost reported revenues. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 have until August 10, 2026 to file a lead plaintiff motion.
06/15/2026, 1:38 PM • Benzinga
A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud involving undisclosed related party transactions, channel stuffing, and inadequate internal controls. The lawsuit covers investors who purchased ADMA securities between August 9, 2024 and March 25, 2026, with a lead plaintiff deadline of August 10, 2026.
06/15/2026, 12:00 PM • GlobeNewswire
A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. for the Class Period between August 9, 2024 and March 25, 2026. Culper Research alleged the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenues. The stock fell 29.1% over two trading days to $9.63 per share following the allegations. Investors have until August 10, 2026 to file a lead plaintiff motion.
06/12/2026, 1:15 PM • Benzinga
A class action lawsuit has been filed against ADMA Biologics, Inc. for alleged securities fraud. Culper Research published a report accusing the company of channel stuffing, undisclosed related party transactions, and inflating revenue growth. The stock fell 29.1% over two trading days following the allegations. Shareholders who purchased ADMA securities between August 9, 2024 and March 25, 2026 can file claims by August 10, 2026.
06/12/2026, 12:06 PM • Benzinga
A securities class action lawsuit has been filed against ADMA Biologics, Inc. for the period between August 9, 2024 and March 25, 2026. The complaint alleges the company engaged in undisclosed related party transactions, used channel stuffing to inflate revenue, and lacked adequate internal controls. Following a critical report by Culper Research on March 24, 2026, ADMA stock fell 16.6% and an additional 15% the next day.
06/11/2026, 2:23 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.